Compare Crispr Therapeutics AG (CRSP) vs Crowdstrike Holdings Inc (CRWD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Crowdstrike Holdings Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Crowdstrike Holdings Inc trades at $275.04 (market cap $269.31B). The key difference: Crowdstrike Holdings Inc is far larger — about 55.2× Crispr Therapeutics AG's market cap, and Crowdstrike Holdings Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Crowdstrike Holdings Inc for 97 Days on average.
| CRSP | CRWD | |
|---|---|---|
Market Cap | $4.88B | $269.31B |
Volume | 2,861,747 | 9,381,560 |
Sector | Health | Technology |
52-Week High | $73.97 | $278.86 |
52-Week Low | $44.34 | $87.56 |
Typical Hold Time | 77 Days | 97 Days |
Enterprise Value | $3.30B | $265.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
CrowdStrike (CRWD) trades at $263.01, down 0.92% on the day but near its 52-week high of $267.69. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings expectations in recent quarters. Revenue growth remains robust, reaching $3.95 billion in 2025, though profitability metrics show modest net income margins. Analyst sentiment is overwhelmingly positive with 76% buy ratings and a consensus price target of $235.74.
CrowdStrike presents a compelling growth story with strong revenue expansion and AI-driven cybersecurity demand, but faces valuation concerns with elevated P/S and P/B ratios. The company's integration with OpenAI Marketplace and identity business growth provide catalysts, while competitive pressures and execution risks remain key considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →
